Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients – – Gemini could potentially ...

Johnson & Johnson has also initiated the Phase 3 ICONIC-ASCEND f study, the first head-to-head study seeking to demonstrate the superiority of an oral tablet, icotrokinra, compared to an injectable ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 ...

Title : APG990, a monoclonal antibody targeting OX40L, demonstrates safety and an extended half-life in healthy subjects (P3237) Presenter : Carl Dambkowski, M.D., Chief Medical Officer, Apogee ...

Lundbeck A/S (Lundbeck) is advancing leadership in migraine with a comprehensive collection of datasets to be presented at the 2025 International Headache Congress, taking place in São Paulo (Sept ...